Performing Credit Quarterly 1Q2021
Oaktree’s latest Performing Credit Quarterly explores how assets from high yield bonds to CLOs responded to rising growth expectations and inflation fears. We discuss the opportunities and risks investors may face in the next stage of this unique recovery.
Life Sciences Direct Lending: Just What the Doctor Ordered
Life sciences is a high-growth industry with a substantial need for capital. Direct lenders may be able to provide funding while keeping risk under control by mixing scientific know-how with second-level thinking. Oaktree’s latest Insights publication discusses why this may be just what the doctor ordered.
Leaning Toward Value: Emerging Markets Equities After the Pandemic
Emerging markets equities, especially cyclical names, may benefit as investors shift from stocks with sticker-shock prices toward those offering possibly attractive returns, but also the potential for reduced risk. Insights discusses why now may be the time to lean toward value in EM.
Commemorating 25 Years of Mastering the Market Cycle
We’re pleased to mark Oaktree’s 25-year anniversary with this timeline of key milestones of our firm alongside major events of the global economy.
Risks and Opportunities in EM amid a Global Slowdown
How are today’s volatile market environment and a global economic slowdown affecting the emerging markets? What are the risks and opportunities for EM-focused investors? Read Oaktree’s latest Special Edition for perspectives on those questions and more.
It’s Not Supposed to be Easy: How Oaktree Strives to Add Value in Uncertain Times
This Special Edition Insights focuses on the myriad ways Oaktree investment professionals seek to add value to investments in today’s uncertain environment.
Direct Lending: Benefits, Risks and Opportunities
Investing in Structured Credit
Investing in Mezzanine Debt